Compare GSK plc (GSK) vs Yum China Holdings Inc (YUMC) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

YUMC trades at $44.42, up 2.58% today, with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.87 exceeding expectations, and maintains solid profitability with a 7.83% net income margin. Recent developments include the acquisition of Pizza Hut's mainland China operations and a $512 million share repurchase plan for H2 2026, signaling management confidence and shareholder returns.

Outlook remains positive due to steady revenue growth, expanding store footprint, and aggressive capital returns, but risks include Chinese consumer spending volatility and integration challenges from the Pizza Hut acquisition. Analyst consensus strongly favors buying, with 74% buy ratings, supporting a constructive view for long-term investors despite near-term macroeconomic headwinds.